Last updated 2026-07-26
- Acquired by Mori Arkin, Jul 2014
- Raised $33.1M Follow-on PO led by TD Cowen, Mar 2026
- Raised $86.3M Follow-on PO led by Jefferies LLC, Jan 2018
Total raised
$159.4M
Last: Undisclosed Round 2008-11
Stage
Public
Founded
1997
Headcount
28
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Sol-Gel Technologies is an experienced dermatology company that leverages innovative approaches to develop advanced treatments for patients with severe skin conditions. They focus on skin diseases that demand therapeutic innovation, aiming to bridge the gap between existing treatments and transformative solutions for patients with rare skin conditions. The company utilizes a proprietary, silica-based microencapsulation technology platform.
Funding history · 6 rounds · $159.4M total
6 events/rounds · $159.4M Total Funding: $30.0M in Private Equity, $129.4M in Public Equity
Mar 2026
★ TD Cowen★ LifeSci CapitalAuGC BioFundAffinity Asset AdvisorsGreat Point Partners, LLCSquadron Capital ManagementTrails Edge Capital PartnersStonepine Capital ManagementSurveyor Capital (a Citadel company)
Apr 2025
★ Mayne Pharma Group Limited
Apr 2020
★ M. Arkin Dermatology Ltd.
Aug 2019
★ Jefferies LLC
Jan 2018
★ Jefferies LLC★ BMO Capital Markets Corp.JMP Securities LLCRaymond James & Associates
Nov 2008
Headcount over time
28 employees (2026-09) · 1 point
Offices
Ness Ziona, Israel · HQ / main office
Q&A
- What is Sol-Gel Technologies' primary focus?
- Sol-Gel Technologies is a dermatology company that develops advanced treatments for patients with severe skin conditions, utilizing a proprietary, silica-based microencapsulation technology platform.
- When was Sol-Gel Technologies acquired and by whom?
- Sol-Gel Technologies was acquired by Mori Arkin in July 2014.
- What was the amount raised in Sol-Gel Technologies' Public Offering in May 2023?
- In May 2023, Sol-Gel Technologies raised $22,800,000 through a Public Offering.
- What was the amount raised in Sol-Gel Technologies' Public Offering in January 2023?
- In January 2023, Sol-Gel Technologies raised $12,800,000 through a Public Offering.
- What was the amount raised in Sol-Gel Technologies' Public Offering in April 2022?
- In April 2022, Sol-Gel Technologies raised $23,000,000 through a Public Offering.
- Which products developed by Sol-Gel Technologies are marketed by Galderma in the US?
- Sol-Gel Technologies successfully developed topical drugs Twyneo and Epsolay for the treatment of acne and inflammatory lesions of rosacea, both of which have been marketed in the US by Galderma since 2022.
- What was the amount raised in Sol-Gel Technologies' Public Offering in February 2020?
- In February 2020, Sol-Gel Technologies raised $23,010,977 through a Public Offering.
- What was the amount raised in Sol-Gel Technologies' Public Offering in August 2019?
- In August 2019, Sol-Gel Technologies raised $10,000,000 through a Public Offering.
- What was the amount raised in Sol-Gel Technologies' Public Offering in May 2019?
- In May 2019, Sol-Gel Technologies raised $15,000,000 through a Public Offering.
- What was the amount raised in Sol-Gel Technologies' Public Offering in February 2018?
- In February 2018, Sol-Gel Technologies raised $75,000,000 through a Public Offering.
Team · 14
Alon Seri-Levy
Founder · Co-Founder & CEO
David Avnir
Founder · Co-Founder
Mori Arkin
Chief Executive Officer, Chairman
Eyal Ben-Or
Chief Financial Officer
Michael Glezin
Chief Business Officer
Ofra Levy-Hacham
VP, Clinical and Regulatory Affairs
Itzik Yosef
Chief Operating Officer
Ofer Toledano
VP, Research and Development
Itai Arkin
Director
Yuval Yanai
Director
Sharon Kochan
Director
Hani Lerman
Director
Ran Gottfried
Director
Jonathan B. Siegel
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterialsBiologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharmaceuticalsdermatologymedicationskin-caretopical-treatmentnanotechnologydrug-deliverychronic-patientsacnelife-sciencescosmetic-companiespharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sol-gel.com/ |
|---|---|
| linkedin.com/company/1117260 | |
| Wikidata | wikidata.org/wiki/Q106411767 |
Identifiers & details
| Legal name | Sol-Gel Technologies Ltd. |
|---|---|
| Founded | 1997 |
| Employees (exact) | 28 |
| Market cap | $117.4M |
| Status reason | Acquired by Mori Arkin on Jul, 2014 |
| Wikidata QID | Q106411767 |
Acquisitions & public offerings
Acquired by Mori Arkin 2014-07
Radar intelligence
Patents
| EPO | 97 |
|---|
Web history (Wayback)
| Domain | sol-gel.com |
|---|
Wikidata
| QID | Q106411767 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512544693 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1997-10-28 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2019 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | גולדה מאיר 7 נס ציונה |